ChinaSecurities

CHENGDU, China, Oct. 5 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co. Inc. (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today declared a quarterly cash dividend to be paid to its common stock shareholders. The dividend of $0.025 will be paid to shareholders of record as of October 30, 2009, with the actual distribution occurring on or about December 10, 2009.

In addition, Tianyin is now eligible to become an S-3 filer which is reserved for companies on a listed exchange that have filed all required reports on a timely basis during the past twelve months. This allows automatic updating of disclosure requirements with the 10-K or 10-Q filings and significantly reduces the costs and resource burdens on the company associated with filing post-effective amendments to the registration statement.

Dr. Jiang Guoqing, Tianyin's Chairman and Chief Executive Officer, commented, "We appreciate the continued support of our shareholders and believe that our strategy of providing a current return and potential capital appreciation resonates well with investors who are looking for growth and income. In addition, this S-3 eligibility will save the company money and resources to meet its filing requirements."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma....

Safe Harbor Statement

The Statements which are not historical facts during the presentation are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
    Allen Tang, Ph.D., MBA, Assistant to the CEO in China
    Tel: +86-158-2122-5642
    Email: Allen.y.tang@gmail.com

    Investors:
    Mr. Matthew Hayden, HC International
    Tel: +1-561-245-5155
    Email: matt.hayden@hcinternational.net
    Web: http://www.hcinternation...